Joshua Siegel, M.D., Ph.D.

Dr. Siegel is a psychiatrist with a doctoral degree in systems neuroscience. Dr. Siegel has published more than 30 peer-reviewed publications in the fields of neuroimaging and neuropsychopharmacology. His primary research focus has been on using systems neuroscience to understand ketamine, psilocybin, and novel molecules that rapidly reverse mood disorders. This work aims to elucidate the complex interplay between neurotransmitters, neurotrophic stimulation, brain networks, mood, and human behavior.

In 2018, Dr. Siegel began work on what would become Missouri’s first human psychedelics clinical study, utilizing precision imaging to study acute and persisting effects of psilocybin on brain networks. He continued this work as junior faculty and also established Washington University’s Program in Psychedelics Research, created a graduate course titled “Mechanisms of Rapid Antidepressants,” and founded the WU Rapid Antidepressants Journal Club. In 2023-2024, Dr. Siegel completed a brief directorship of Translational Medicine at Sunovion/Sumitomo Pharma, where he led biomarker programs for early-phase compounds with potential in depression, Parkinson’s Disease, epilepsy, and other CNS indications. In 2024, he joined the faculty at NYU Langone Center for Psychedelic Medicine and Nathan Kline Institute for Psychiatric Research, with aspirations to bring his expertise in translational neuroscience and target engagement to these world-leading research organizations.